Gilead Sciences Inc. (GILD) ended last trading session with a change of -0.56 percent. It trades at an average volume of 10.45M shares versus 8.32M shares recorded at the end of last trading session. The share price of $77.62 is at a distance of 1.24 percent from its 52-week low and down -30.48 percent versus its peak. The company has a market cap of $103.67B and currently has 1.34B shares outstanding. The share price is currently -1.94 percent versus its SMA20, -4.82 percent versus its SMA50, and -12.33 percent versus its SMA200. The stock has a weekly performance of -0.77 percent and is -22.49 percent year-to-date as of the recent close.
On August 23, 2016 Gilead Sciences, Inc. (GILD) announced that Kelly A. Kramer has been appointed to the company’s Board of Directors and Audit Committee.
Ms. Kramer is currently Executive Vice President and Chief Financial Officer of Cisco Systems, Inc., which designs and sells products, services and solutions to securely connect everyone and everything. She previously served for 20 years in senior finance positions at General Electric, including as Chief Financial Officer of GE Healthcare’s Healthcare Systems Business. She is a member of the board of the Silicon Valley Chapter of City Year, a non-profit organization that provides educational support for at-risk students in poor communities.
Opko Health, Inc. (OPK) recently recorded 1.49 percent change and currently at $10.19 is 43.12 percent away from its 52-week low and down -14.01 percent versus its peak. It has a past 5-day performance of 6.26 percent and trades at an average volume of 3.23M shares. The stock has a 1-month performance of 1.09 percent and is 1.39 percent year-to-date as of the recent close. There were about 559.42M shares outstanding which made its market cap $5.7B. The share price is currently 6.63 percent versus its SMA20, 4.15 percent versus its SMA50, and 4.11 percent versus its SMA200.
On September 13, 2016 OPKO Health, Inc. (OPK) announced the appointment of Jane Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories, effective October 1, 2016.
Ms. Wood is a nationally respected healthcare attorney who has been practicing law for 29 years. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 pathology groups and 350 clinical laboratories. For the past 28 years she has been with the multi-state law firm McDonald Hopkins LLC, where she is a member of the firm’s board of directors. Ms. Wood is a frequent speaker at national and state laboratory and pathology meetings, is a contributor to association publications and is regularly quoted in the national press. Ms. Wood graduated from the Vanderbilt University School of Law.